T-Cell Infiltration and Immune Checkpoint Expression Increase in Oral Cavity Premalignant and Malignant Disorders.

immune cell infiltration immune checkpoint immunotherapy oncogenesis oral cancer oral potentially malignant disorders tumor microenvironment tumorigenesis

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
30 Jul 2022
Historique:
received: 30 06 2022
revised: 21 07 2022
accepted: 26 07 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

The immune cell niche associated with oral dysplastic lesion progression to carcinoma is poorly understood. We identified T regulatory cells (Treg), CD8+ effector T cells (Teff) and immune checkpoint molecules across oral dysplastic stages of oral potentially malignant disorders (OPMD). OPMD and oral squamous cell carcinoma (OSCC) tissue sections (N = 270) were analyzed by immunohistochemistry for Treg (CD4, CD25 and FoxP3), Teff (CD8) and immune checkpoint molecules (PD-1 and PD-L1). The Treg marker staining intensity correlated significantly (p < 0.01) with presence of higher dysplasia grade and invasive cancer. These data suggest that Treg infiltration is relatively early in dysplasia and may be associated with disease progression. The presence of CD8+ effector T cells and the immune checkpoint markers PD-1 and PD-L1 were also associated with oral cancer progression (p < 0.01). These observations indicate the induction of an adaptive immune response with similar Treg and Teff recruitment timing and, potentially, the early induction of exhaustion. FoxP3 and PD-L1 levels were closely correlated with CD8 levels (p < 0.01). These data indicate the presence of reinforcing mechanisms contributing to the immune suppressive niche in high-risk OPMD and in OSCC. The presence of an adaptive immune response and T-cell exhaustion suggest that an effective immune response may be reactivated with targeted interventions coupled with immune checkpoint inhibition.

Identifiants

pubmed: 36009387
pii: biomedicines10081840
doi: 10.3390/biomedicines10081840
pmc: PMC9404942
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34130988
Clin Oral Investig. 2019 Apr;23(4):1913-1919
pubmed: 30229300
Head Neck. 2016 Jul;38(7):1074-84
pubmed: 26879675
Ann Oncol. 2016 Aug;27(8):1492-504
pubmed: 27207108
J Oncol. 2011;2011:603740
pubmed: 21772845
Life Sci. 2016 Jan 15;145:74-84
pubmed: 26679106
Cancers (Basel). 2021 Jan 21;13(3):
pubmed: 33494389
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Int J Oral Maxillofac Surg. 2019 Oct;48(10):1279-1288
pubmed: 31053518
Int J Oral Sci. 2021 Aug 2;13(1):24
pubmed: 34341329
Oncotarget. 2017 Jan 10;8(2):2171-2186
pubmed: 27974689
Cancer Immunol Immunother. 2020 Mar;69(3):465-476
pubmed: 31950224
Pathol Res Pract. 2019 Jun;215(6):152418
pubmed: 31027907
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32753468
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806906
pubmed: 30407116
J Immunol. 2017 Feb 1;198(3):986-992
pubmed: 28115587
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Oral Oncol. 2017 Dec;75:140-147
pubmed: 29224811
Oncoimmunology. 2017 Sep 14;7(1):e1364828
pubmed: 29296515
Int J Oral Sci. 2021 Apr 1;13(1):13
pubmed: 33795644
Sci Rep. 2021 Jan 12;11(1):775
pubmed: 33436863
Redox Biol. 2019 Jul;25:101174
pubmed: 30917934
Pathol Oncol Res. 2018 Jul;24(3):497-505
pubmed: 28669079
Oncoimmunology. 2018 Sep 21;7(12):e1496880
pubmed: 30524889
J Cancer. 2013;4(1):66-83
pubmed: 23386906
Front Immunol. 2020 Feb 13;11:167
pubmed: 32117298
Cancer Gene Ther. 2022 Jan;29(1):10-21
pubmed: 33603130
Exp Ther Med. 2021 Aug;22(2):834
pubmed: 34149880
Transl Oncol. 2021 Feb;14(2):100994
pubmed: 33333370
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167
pubmed: 28619999
Sci Rep. 2017 Aug 8;7(1):7522
pubmed: 28790303
Br J Cancer. 2014 Jan 21;110(2):501-9
pubmed: 24129245
Oncotarget. 2017 May 2;8(32):52889-52900
pubmed: 28881780
Head Neck. 2010 Jul;32(7):946-58
pubmed: 20191626
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Cancer Prev Res (Phila). 2017 Dec;10(12):681-683
pubmed: 29138137
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Scand J Immunol. 2012 Jul;76(1):39-48
pubmed: 22469080
Biomedicines. 2021 Jun 08;9(6):
pubmed: 34201050
Clin Cancer Res. 2005 Apr 15;11(8):2947-53
pubmed: 15837746
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
Front Immunol. 2020 Sep 10;11:2105
pubmed: 33013886
Br J Cancer. 2002 May 6;86(9):1444-8
pubmed: 11986779
Adv Cancer Res. 2015;128:263-307
pubmed: 26216636

Auteurs

Subin Surendran (S)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Usama Aboelkheir (U)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Andrew A Tu (AA)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

William J Magner (WJ)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

S Lynn Sigurdson (SL)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Mihai Merzianu (M)

Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Wesley L Hicks (WL)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Amritha Suresh (A)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Integrated Head and Neck Oncology Program, Mazumdar Shaw Medical Foundation Bangalore, Bangalore 560099, India.

Keith L Kirkwood (KL)

Periodontics and Endodontics, University at Buffalo School of Dental Medicine, Buffalo, NY 14214, USA.

Moni A Kuriakose (MA)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Integrated Head and Neck Oncology Program, Mazumdar Shaw Medical Foundation Bangalore, Bangalore 560099, India.

Classifications MeSH